A novel anoikis-related gene signature predicts prognosis in patients with breast cancer and reveals immune infiltration

Chaoyi Tang,Liuqing Qin,Jiehua Li
DOI: https://doi.org/10.1097/md.0000000000035732
IF: 1.6
2024-02-10
Medicine
Abstract:Breast cancer is the most common malignancy and second leading cause of death in women. It accounts for 31% of all incident cases and 15% of all deaths in females. [ 1 ] The current treatment approach for breast cancer involves surgical resection combined with radiation therapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and endocrine therapy. The progression of tumor development from normal cells to cancer cells is influenced by the deterioration of the patient's health and proliferation of tumorigenic factors. Throughout this process, cancer cells accumulate mutations and differentiate into different genetic lineages and subgroups, resulting in tumor heterogeneity. [ 2 ] Tumor heterogeneity, which is closely linked to the invasive and metastatic potential of tumors, affects clinical diagnosis, treatment, and prognosis. [ 3 ] Therefore, it is crucial to identify reliable and efficient clinical therapeutic techniques and biomarkers to improve the survival and cure rates of breast cancer patients.
medicine, general & internal
What problem does this paper attempt to address?